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Background: Patients with diabetes are prone to a diffuse and rapidly progressive form of atherosclerosis. It is not known whether there are 
differences in the effectiveness of newer-generation everolimus-eluting stents and early generation sirolimus-eluting stents in the high-risk subgroup 
of patients with diabetes mellitus.
Methods: Between 2008 and 2009, a total of 6169 patients (2159 patients [35%] with medically treated diabetes) were treated with everolimus-
eluting stents (3084 patients) or sirolimus-eluting stents (3085 patients), as the part of the Interventional Cardiology Research Incooperation 
Society (IRIS)-Drug-Eluting Stents (DES) Registry. The primary end point was the incidence of major adverse cardiac events (MACE) at 12 -months, 
defined as a composite of death, nonfatal myocardial infarction (MI), or target-vessel revascularization (TVR).
Results: After multivariable adjustment for differences in baseline characteristics, there were no significant between-group differences in the rate 
of 12-month MACE in diabetic patients (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.58-1.57, P=0.85). There were also no significant 
between-group differences in the rate of death, MI, TVR, or stent thrombosis in diabetic patients. However, in non-diabetic patients, there was trend 
toward lower incidence of MACE after everolimus-eluting stents than after sirolimus-eluting stents (HR, 0.70; 95% CI, 0.45-1.07, P=0.10). There were 
no significant between-group differences in the rate of death, MI, TVR, or stent thrombosis in non-diabetic patients, but the adjusted risk of death 
was significantly lower in the everolimus-eluting stents group than in the sirolimus-eluting stent group (HR, 0.39; 95% CI, 0.19-0.81, P=0.01).
Conclusions: During 1-year follow-up, as compared with early generation sirolimus-eluting stents, everolimus-eluting stent resulted in similar rates 
of MACE in diabetic patients, but resulted in lower incidence of MACE in non-diabetic patients with difference in mortality.
